Strategic Merger Vapotherm recently closed a merger with an affiliate of Perceptive Advisors, signaling new strategic capital and potential expansion capabilities that sales teams can leverage to approach larger hospital systems and procurement channels with enhanced financing and go-to-market resources.

Financial Momentum With quarterly financial results and a merger close in 2024, Vapotherm presents an opportunity to position high velocity therapy equipment as part of its growth narrative to hospitals seeking scalable respiratory support solutions and updated technology platforms.

Clinical Reach The Precision Flow system targets ED and ICU patients requiring heated humidified high flow therapy, presenting cross-sell opportunities to neighboring departments such as pulmonology, critical care, and emergency medicine within mid to large care facilities.

Regulatory & Sustainability The company’s tech stack includes ISO 14001 certification, signaling a commitment to environmental management; highlight sustainability and regulatory compliance as value props when engaging procurement teams prioritizing green and compliant medical devices.

Market Positioning Vapotherm operates in a competitive medical equipment space with peers of varying scale; emphasize differentiated high velocity, mask-free therapy capabilities and a proven track record in respiratory distress therapy to win contracts against larger incumbents.